Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
TIAMATE (diltiazem malate) is an oral extended-release calcium channel blocker approved in 1996 for cardiovascular indications. Diltiazem works by inhibiting calcium influx into vascular smooth muscle and cardiac cells, reducing heart rate and blood pressure. It is used primarily in hypertension and angina management.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on managed decline and cost containment rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TIAMATE offers limited growth trajectory but valuable experience in mature product management, generic transition strategy, and cost-containment initiatives. This role suits professionals seeking to develop expertise in portfolio rationalization or preparing for career pivot to higher-growth franchises.
Worked on TIAMATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo